Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics crawled date : 2020 - 12 - 01 save search
Predictive Oncology Completes Acquisition of Soluble Therapeutics and BioDtech
Published: 2020-06-02 (Crawled : 22:17) - globenewswire.com
POAI | $1.26 6.78% 6.35% 66K
|
Health Technology
|
| O: 3.12%
H: 1.82%
C: 1.82%
biotech acquisition therapeutics
Onconova Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results
Published: 2020-05-14 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 11.11%
H: 0.2%
C: -9.78%
results
Onconova Therapeutics Announces Presentation at BIO Digital 2020
Published: 2020-06-08 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 3.33%
H: 6.69%
C: -0.06%
presentation therapeutics
Onconova Therapeutics Announces Presentation at the 25th Congress of the European Hematology Association (EHA)
Published: 2020-06-12 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 3.97%
H: 9.68%
C: -2.11%
Onconova Therapeutics Announces the Initiation of a Phase 1/2a Study of Rigosertib plus Nivolumab for the Treatment of KRAS+ Lung Adenocarcinoma
Published: 2020-06-22 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 3.79%
H: 6.33%
C: 2.38%
treatment phase 3 phase 1 phase 2 nivolumab
Onconova Therapeutics Announces Participation in Noble Capital Markets Investor Webinar
Published: 2020-06-23 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 3.37%
H: 0.79%
C: -3.97%
therapeutics market
Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS
Published: 2020-07-07 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: -1.07%
H: 4.7%
C: 2.69%
risk results leukemia research phase 3 phase 1 phase 2
Onconova Therapeutics Announces Publication of Preclinical Data Supporting Rigosertib’s Mechanism of Action as a Targeted Anticancer Therapy
Published: 2020-07-23 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 6.72%
H: 2.36%
C: -10.24%
therapy cancer preclinical pre-clinical
Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease
Published: 2020-07-27 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 12.61%
H: 0.0%
C: -0.8%
covid disease application
Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis
Published: 2020-07-29 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: -1.77%
H: 24.32%
C: 15.32%
phase 3 trial
Onconova Therapeutics Announces Compliance with Nasdaq Bid Price Requirement
Published: 2020-08-04 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: -2.63%
H: 2.7%
C: -0.9%
therapeutics nasdaq
Onconova Therapeutics to Provide Corporate Update and Second Quarter 2020 Earnings on August 12, 2020
Published: 2020-08-07 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: -3.29%
H: 11.65%
C: 10.68%
Onconova Therapeutics Highlights Corporate Progress and Reports Second Quarter 2020 Financial Results
Published: 2020-08-12 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: -0.94%
H: 0.0%
C: -3.81%
results
Onconova Therapeutics Announces Topline Results from the Pivotal Phase 3 INSPIRE Trial
Published: 2020-08-24 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: -72.75%
H: 44.62%
C: 24.6%
results phase 3 trial topline
Onconova Therapeutics Announces Election of James J. Marino, JD, MBA as Chairman of the Board of Directors
Published: 2020-08-31 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 0.04%
H: 0.77%
C: -12.12%
Onconova Therapeutics Announces Participation at Upcoming Virtual Events
Published: 2020-09-09 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 0.0%
H: 7.52%
C: 5.01%
therapeutics
Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals
Published: 2020-09-21 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 24.3%
H: 9.9%
C: -9.03%
china biopharma trial phase 3 phase 1 phase 2
Onconova Therapeutics to Present Update During the 2020 BIO Investor Forum Digital Event
Published: 2020-10-13 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 0.67%
H: 25.74%
C: 23.64%
Onconova Therapeutics to Provide Corporate Update and Third Quarter 2020 Financial Results on November 12, 2020
Published: 2020-11-05 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: -0.2%
H: 4.97%
C: 2.23%
results
Onconova Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
Published: 2020-11-12 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: -8.36%
H: 0.97%
C: -1.08%
results
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.